Ani Pharmaceuticals Stock Net Income
| ANIP Stock | USD 56.91 1.05 1.88% |
ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 18.8 M | 19.7 M | |
| Net Income From Continuing Ops | 13.4 M | 14.1 M | |
| Net Loss | -44.6 M | -42.3 M | |
| Net Income Per Share | 1.04 | 1.10 | |
| Net Income Per E B T | 0.94 | 0.50 |
ANI | Net Income |
ANI Pharmaceuticals Company Net Income Analysis
ANI Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current ANI Pharmaceuticals Net Income | 18.78 M |
Most of ANI Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ANI Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Net Income. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ANI Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ANI Pharmaceuticals reported net income of 18.78 M. This is 94.5% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 96.71% higher than that of the company.
ANI Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.ANI Pharmaceuticals is currently under evaluation in net income category among its peers.
ANI Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ANI Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in ANI Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ANI Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ANI Pharmaceuticals' value.| Shares | Tang Capital Management Llc | 2024-09-30 | 450 K | Geode Capital Management, Llc | 2024-09-30 | 425.2 K | Macquarie Group Ltd | 2024-06-30 | 388.1 K | Nuveen Asset Management, Llc | 2024-06-30 | 319.1 K | Amvescap Plc. | 2024-06-30 | 311.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 250.3 K | Renaissance Technologies Corp | 2024-09-30 | 245.1 K | Ameriprise Financial Inc | 2024-06-30 | 233.4 K | Thompson, Siegel & Walmsley Llc | 2024-09-30 | 230.2 K | Blackrock Inc | 2024-06-30 | 2.7 M | Vanguard Group Inc | 2024-09-30 | 1.3 M |
ANI Fundamentals
| Return On Equity | -0.016 | ||||
| Return On Asset | 0.0125 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 1.69 B | ||||
| Shares Outstanding | 21.02 M | ||||
| Shares Owned By Insiders | 11.10 % | ||||
| Shares Owned By Institutions | 99.67 % | ||||
| Number Of Shares Shorted | 2.16 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 2.95 X | ||||
| Price To Sales | 2.15 X | ||||
| Revenue | 486.82 M | ||||
| Gross Profit | 177.6 M | ||||
| EBITDA | 109.32 M | ||||
| Net Income | 18.78 M | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 285.67 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 20.74 X | ||||
| Cash Flow From Operations | 118.96 M | ||||
| Short Ratio | 11.73 X | ||||
| Earnings Per Share | (0.47) X | ||||
| Price To Earnings To Growth | 1.06 X | ||||
| Target Price | 78.4 | ||||
| Number Of Employees | 642 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 1.2 B | ||||
| Total Asset | 904.42 M | ||||
| Retained Earnings | (80.13 M) | ||||
| Working Capital | 374.34 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
| Net Asset | 904.42 M |
About ANI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against ANI Stock
| 0.4 | VRDN | Viridian Therapeutics | PairCorr |
| 0.35 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.31 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.